RARA and acute myeloid leukemia: Figs. 1D and E present an example of the involvement of quizartinib, pathway Martens–PML–RARA [20], and AML, where the correlation between PAS and AUC is −0.14 in the GDSC cohort and −0.20 in the BeatAML cohort.